VRTXHealthcare · BiotechnologyThe 31 Wall Street analysts covering Vertex Pharmaceuticals, Inc. hold a median 12-month price target of $575 — +11.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 23 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Vertex Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Accruals (28): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.4% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | JP Morgan | Reinstates | Overweight | $515 → $560 |
| 2 Sept 2026 | Morgan Stanley | Reinstates | Overweight | $665 |
| 5 Aug 2026 | Barclays | Maintains | Overweight | — |
| 5 Aug 2026 | Barclays | Maintains | Overweight | $615 → $617 |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | $560 → $565 |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Hold | $436 → $442 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 4 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 4 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $590 → $595 |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | $525 → $550 |
| 13 July 2026 | Truist Securities | Maintains | Buy | — |
| 13 July 2026 | Truist Securities | Maintains | Buy | $542 → $560 |
| 13 July 2026 | UBS | Maintains | Buy | — |
| 13 July 2026 | UBS | Maintains | Buy | $545 → $585 |
| 7 July 2026 | Baird | Maintains | Underperform | $330 → $350 |
| 7 July 2026 | Baird | Maintains | Underperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $543 → $570 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Sept 2026, Vertex Pharmaceuticals, Inc. returned +36.0% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 25% of US stocks
Cheaper than 14% of US stocks
Cheaper than 16% of US stocks
Cheaper than 11% of US stocks
Higher than 58% of US stocks
Higher than 43% of US stocks
Higher than 94% of US stocks
Higher than 91% of US stocks
Higher than 92% of US stocks
Higher than 84% of US stocks
Higher than 95% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vertex Pharmaceuticals, Inc. has a market value of $129.4B and an enterprise value of $123.6B.
Revenue in the twelve months to 30 June 2026: $12.6B. The latest quarter grew 12.5% year on year.
Net income over the same four quarters: $4.4B, a 35.0% net margin.
Diluted earnings per share, trailing twelve months: $17.18.
Free cash flow in the twelve months to 30 June 2026: $3.8B.
Vertex Pharmaceuticals, Inc. spent $2.3B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 29.7×; forward P/E: 25.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Vertex Pharmaceuticals, Inc. employs 6,400 people — $2.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vertex Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vertex announced positive Phase II AMPLIFIED data for its kidney disease drug inaxaplin, and has completed enrollment in the AMPLITUDE study, with interim results targeted for early 2027.
Why it matters — A VRTX watcher would care because positive Phase II data and completed enrollment advance the inaxaplin kidney disease program toward a key interim readout in early 2027.
Vertex Pharmaceuticals reported data from its Phase 2b AMPLIFIED trial of inaxaplin in patients with APOL1-mediated kidney disease (AMKD). The company characterized the results as encouraging, describing the drug as underappreciated.
Why it matters — The trial results represent a significant clinical update for inaxaplin, a potential treatment for AMKD that could expand Vertex's product portfolio beyond its core cystic fibrosis franchise.
Vertex Pharmaceuticals shares rose on Tuesday after an unexpected expansion of its kidney disease drug program, a development that also sent shares of rival Maze Therapeutics sharply higher.
Why it matters — Vertex investors would care because the surprise expansion in its kidney disease pipeline lifted Vertex's stock and signals potential broadening of a key therapeutic focus.
Zacks.com users have been showing increased attention to Vertex Pharmaceuticals (VRTX), prompting an examination of the stock's outlook. The article highlights that the company is currently a trending stock among investors on the platform.
Why it matters — The rising investor interest in VRTX indicates that market attention on the company is growing, which could influence its visibility and trading activity.
Vertex announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) with modest proteinuria and in those with AMKD and type 2 diabetes. The company also reported completion of enrollment in the Phase 2/3 AMPLITUDE trial.
Why it matters — These positive results and completed enrollment signal progress for inaxaplin, a potential new treatment for additional AMKD patient populations, which could expand Vertex's therapeutic reach in kidney disease.
The 31 Wall Street analysts covering Vertex Pharmaceuticals, Inc. have a median 12-month price target of $575, with estimates ranging from $350 to $672. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 31 analysts covering Vertex Pharmaceuticals, Inc., 25 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Vertex Pharmaceuticals, Inc. 76 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, Vertex Pharmaceuticals, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 31 analysts implies +11.4% from the last close, and Ticker Nerd's factor model ranks Vertex Pharmaceuticals, Inc. 76 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vertex Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $350 to $672 over the next 12 months.
Vertex Pharmaceuticals, Inc. returned +36.0% over the 12 months to 23 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX.
The most recent item we track (Zacks Investment Research, 23 Sept 2026): "Vertex Posts Positive Phase II Data on Kidney Disease Drug". Vertex announced positive Phase II AMPLIFIED data for its kidney disease drug inaxaplin, and has completed enrollment in the AMPLITUDE study, with interim results targeted for early 2027.
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX. Vertex serves patients across the United States, Europe, and other international markets, with a business model that combines specialized research, regulatory development, manufacturing, and commercialization capabilities. The company is known for operating in highly scientific and tightly regulated therapeutic markets, where innovation, clinical expertise, and product execution are central to its role. Vertex Pharmaceuticals Incorporated Common Stock is used by investors to track and participate in the performance of a biotechnology business with a strong presence in specialty pharmaceuticals and advanced medicine development.
CEO Dr. Reshma Kewalramani FASN, M.D. · 6,400 employees · United States · https://www.vrtx.com
